The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study
to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had
an inadequate response or intolerance to methotrexate.